These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 33260548)

  • 1. Identification of Enzymes Oxidizing the Tyrosine Kinase Inhibitor Cabozantinib: Cabozantinib Is Predominantly Oxidized by CYP3A4 and Its Oxidation Is Stimulated by cyt b
    Indra R; Vavrová K; Pompach P; Heger Z; Hodek P
    Biomedicines; 2020 Nov; 8(12):. PubMed ID: 33260548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Human Enzymes Oxidizing the Anti-Thyroid-Cancer Drug Vandetanib and Explanation of the High Efficiency of Cytochrome P450 3A4 in its Oxidation.
    Indra R; Pompach P; Martínek V; Takácsová P; Vavrová K; Heger Z; Adam V; Eckschlager T; Kopečková K; Arlt VM; Stiborová M
    Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31295928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of individual human cytochrome P450 enzymes on oxidative metabolism of anticancer drug lenvatinib.
    Vavrová K; Indra R; Pompach P; Heger Z; Hodek P
    Biomed Pharmacother; 2022 Jan; 145():112391. PubMed ID: 34847475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tyrosine kinase inhibitors vandetanib, lenvatinib and cabozantinib modulate oxidation of an anticancer agent ellipticine catalyzed by cytochromes P450 in vitro.
    Kolarik M; Indra R; Adam V; Heger Z; Kopeckova K; Arlt VM; Stiborova M
    Neuro Endocrinol Lett; 2019 Feb; 39(7):515-524. PubMed ID: 30860683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytochrome
    Stiborová M; Indra R; Frei E; Kopečková K; Schmeiser HH; Eckschlager T; Adam V; Heger Z; Arlt VM; Martínek V
    Monatsh Chem; 2017; 148(11):1983-1991. PubMed ID: 29104319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular characterization of specifically active recombinant fused enzymes consisting of CYP3A4, NADPH-cytochrome P450 oxidoreductase, and cytochrome b5.
    Inui H; Maeda A; Ohkawa H
    Biochemistry; 2007 Sep; 46(35):10213-21. PubMed ID: 17691855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ellipticine oxidation and DNA adduct formation in human hepatocytes is catalyzed by human cytochromes P450 and enhanced by cytochrome b5.
    Stiborová M; Poljaková J; Martínková E; Ulrichová J; Simánek V; Dvořák Z; Frei E
    Toxicology; 2012 Dec; 302(2-3):233-41. PubMed ID: 22917556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxidation of 3-aminobenzanthrone, a human metabolite of carcinogenic environmental pollutant 3-nitrobenzanthrone, by cytochromes P450 - similarity between human and rat enzymes.
    Mizerovska J; Dracinska H; Arlt VM; Schmeiser HH; Frei E; Stiborova M
    Neuro Endocrinol Lett; 2009; 30 Suppl 1():52-9. PubMed ID: 20027145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites.
    Sutton D; Butler AM; Nadin L; Murray M
    J Pharmacol Exp Ther; 1997 Jul; 282(1):294-300. PubMed ID: 9223567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP2C9 protein interactions with cytochrome b(5): effects on the coupling of catalysis.
    Locuson CW; Wienkers LC; Jones JP; Tracy TS
    Drug Metab Dispos; 2007 Jul; 35(7):1174-81. PubMed ID: 17446262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of human CYP3A4 in the biotransformation of sorafenib to its major oxidized metabolites.
    Ghassabian S; Rawling T; Zhou F; Doddareddy MR; Tattam BN; Hibbs DE; Edwards RJ; Cui PH; Murray M
    Biochem Pharmacol; 2012 Jul; 84(2):215-23. PubMed ID: 22513143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sudan I is a potential carcinogen for humans: evidence for its metabolic activation and detoxication by human recombinant cytochrome P450 1A1 and liver microsomes.
    Stiborová M; Martínek V; Rýdlová H; Hodek P; Frei E
    Cancer Res; 2002 Oct; 62(20):5678-84. PubMed ID: 12384524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation.
    Butler AM; Murray M
    J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Roles of NADPH-P450 reductase and apo- and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli.
    Yamazaki H; Nakamura M; Komatsu T; Ohyama K; Hatanaka N; Asahi S; Shimada N; Guengerich FP; Shimada T; Nakajima M; Yokoi T
    Protein Expr Purif; 2002 Apr; 24(3):329-37. PubMed ID: 11922748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of human cytochrome P450 isozymes responsible for the in vitro oxidative metabolism of finasteride.
    Huskey SW; Dean DC; Miller RR; Rasmusson GH; Chiu SH
    Drug Metab Dispos; 1995 Oct; 23(10):1126-35. PubMed ID: 8654202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reconstitution of recombinant cytochrome P450 2C10(2C9) and comparison with cytochrome P450 3A4 and other forms: effects of cytochrome P450-P450 and cytochrome P450-b5 interactions.
    Yamazaki H; Gillam EM; Dong MS; Johnson WW; Guengerich FP; Shimada T
    Arch Biochem Biophys; 1997 Jun; 342(2):329-37. PubMed ID: 9186495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro identification of metabolic pathways and cytochrome P450 enzymes involved in the metabolism of etoperidone.
    Yan Z; Caldwell GW; Wu WN; McKown LA; Rafferty B; Jones W; Masucci JA
    Xenobiotica; 2002 Nov; 32(11):949-62. PubMed ID: 12487725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of CYP2C9 activity and hydrogen peroxide production by cytochrome b
    Gómez-Tabales J; García-Martín E; Agúndez JAG; Gutierrez-Merino C
    Sci Rep; 2020 Sep; 10(1):15571. PubMed ID: 32968106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro characterization of the metabolism of haloperidol using recombinant cytochrome p450 enzymes and human liver microsomes.
    Fang J; McKay G; Song J; Remillrd A; Li X; Midha K
    Drug Metab Dispos; 2001 Dec; 29(12):1638-43. PubMed ID: 11717183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coexpression of genetically engineered fused enzyme between yeast NADPH-P450 reductase and human cytochrome P450 3A4 and human cytochrome b5 in yeast.
    Hayashi K; Sakaki T; Kominami S; Inouye K; Yabusaki Y
    Arch Biochem Biophys; 2000 Sep; 381(1):164-70. PubMed ID: 11019832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.